Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
CSTL

CSTL - Castle Biosciences Inc Stock Price, Fair Value and News

$20.71-0.30 (-1.43%)
Delayed as of 12 Jun 2026, 04:00 pm ET

70/100

CSTL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

CSTL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CSTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CSTL Price Action

Last 7 days

-1.4%

Last 30 days

14.1%

Last 90 days

-19.0%

Trailing 12 Months

10.0%

CSTL RSI Chart

CSTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CSTL Valuation

Market Cap

627.4M

Price/Earnings (Trailing)

-48.9

Price/Sales (Trailing)

1.85

Price/Free Cashflow

138.87

CSTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CSTL Fundamentals

CSTL Revenue

Revenue (TTM)

339.9M

Rev. Growth (Yr)

-4.9%

Rev. Growth (Qtr)

-3.83%

CSTL Earnings

Earnings (TTM)

-12.8M

Earnings Growth (Yr)

43.82%

Earnings Growth (Qtr)

-522.73%

CSTL Profitability

Operating Margin

77.88%

Return on Equity

-2.78%

Return on Assets

-2.34%

Free Cashflow Yield

0.72%

CSTL Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

5.03%

Diluted EPS (TTM)

-0.42

CSTL Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026339.9M000
2025347.1M346.3M343.5M344.2M
2024250.7M287.6M311.9M332.1M
2023152.2M167.5M192.0M219.8M
202298.1M110.2M123.7M137.0M
202168.0M78.1M86.3M94.1M
202060.6M62.5M63.0M62.6M
201927.8M34.6M45.7M51.9M
201800022.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Castle Biosciences Inc

CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
 CEO
 WEBSITEhttps://castlebiosciences.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES582

Castle Biosciences Inc Frequently Asked Questions

CSTL is the stock ticker symbol of Castle Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Castle Biosciences Inc is 627.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, CSTL's PE ratio (Price to Earnings) is -48.9 and Price to Sales (PS) ratio is 1.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSTL PE ratio will change depending on the future growth rate expectations of investors.